Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2026)
Denali Therapeutics' (DNLI) quarterly Income from Continuing Operations came in at 129013000.0 in Q1 2026, up 5.05% year-on-year from 122814858.51 in Q1 2025, and up 1.84% on a QoQ basis from 131427000.0 in Q4 2025.
Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has 10 years of Income from Continuing Operations data on file, last reported at 129013000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 5.05% year-over-year to 129013000.0 in Q1 2026; TTM through Mar 2026 was 562549000.0, a 20.88% decrease from a year earlier, with the FY2025 full-year figure at 512540000.0, down 21.23% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 129013000.0, up from 131427000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for DNLI reached as high as 183383000.0 in Q2 2023 and fell as low as 172227000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 94744000.0 across 5 years, with a median of 110077000.0 in 2024.
- Across the five-year window, Income from Continuing Operations surged 411.91% in 2023 and tumbled 155.56% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 98678000.0 in 2022, then fell by 21.07% to 119473000.0 in 2023, then increased by 1.59% to 117570000.0 in 2024, then decreased by 11.79% to 131427000.0 in 2025, then rose by 1.84% to 129013000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 129013000.0 in Q1 2026, 131427000.0 in Q4 2025, and 129882000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Denali Therapeutics | 4.37 Bn | 4.37 Bn | - | -129.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -129.01 Mn |
| Dec 31, 2025 | -131.43 Mn |
| Sep 30, 2025 | -129.88 Mn |
| Jun 30, 2025 | -172.23 Mn |
| Mar 31, 2025 | -135.87 Mn |
| Dec 31, 2024 | -117.57 Mn |
| Sep 30, 2024 | -110.08 Mn |
| Jun 30, 2024 | -101.88 Mn |
| Mar 31, 2024 | -104.60 Mn |
| Dec 31, 2023 | -119.47 Mn |
| Sep 30, 2023 | -99.35 Mn |
| Jun 30, 2023 | 183.38 Mn |
| Mar 31, 2023 | -112.78 Mn |
| Dec 31, 2022 | -98.68 Mn |
| Sep 30, 2022 | -103.30 Mn |
| Jun 30, 2022 | -58.79 Mn |
| Mar 31, 2022 | -69.12 Mn |
| Dec 31, 2021 | -75.26 Mn |
| Sep 30, 2021 | -84.59 Mn |
| Jun 30, 2021 | -60.69 Mn |